Payment overview · 2025
General Payments
$83.79
5 reported records · 4 companies
Healthcare provider profile · identity verified
Derrick W Taylor, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FITZGERALD, GA · NPI 1811983091
Verified facts
What the public records show
CMS Open Payments records show Derrick W Taylor, MD received $83.79 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 36.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.94 | 36.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.81 | 22.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.33 | 21.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.71 | 18.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $83.79 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.94 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 201 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 69 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
201 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1232 | 326 |
| Atorvastatin Calcium | Atorvastatin Calcium | 988 | 259 |
| Losartan Potassium | Losartan Potassium | 926 | 259 |
| Levothyroxine Sodium | Levothyroxine Sodium | 617 | 140 |
| Gabapentin | Gabapentin | 615 | 148 |
| Metoprolol Succinate | Metoprolol Succinate | 581 | 153 |
| Pravastatin Sodium | Pravastatin Sodium | 568 | 154 |
| Lisinopril | Lisinopril | 486 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 484 | 138 |
| Potassium Chloride | Potassium Chloride | 402 | 110 |
| Tramadol Hcl | Tramadol Hcl | 387 | 94 |
| Eliquis | Apixaban | 362 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 362 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 348 | 97 |
| Omeprazole | Omeprazole | 335 | 96 |
| Pioglitazone Hcl | Pioglitazone Hcl | 335 | 90 |
| Furosemide | Furosemide | 334 | 102 |
| Metformin Hcl | Metformin Hcl | 318 | 84 |
| Metformin Hcl Er | Metformin Hcl | 317 | 87 |
| Famotidine | Famotidine | 310 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 308 | 95 |
| Carvedilol | Carvedilol | 285 | 68 |
| Hydralazine Hcl | Hydralazine Hcl | 284 | 60 |
| Tizanidine Hcl | Tizanidine Hcl | 214 | 68 |
| Jardiance | Empagliflozin | 205 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 202 | 48 |
| Ozempic | Semaglutide | 201 | 37 |
| Montelukast Sodium | Montelukast Sodium | 200 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 199 | 46 |
| Clonazepam | Clonazepam | 193 | 41 |
| Alprazolam | Alprazolam | 186 | 43 |
| Allopurinol | Allopurinol | 184 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 179 | 47 |
| Trazodone Hcl | Trazodone Hcl | 172 | 50 |
| Synthroid | Levothyroxine Sodium | 165 | 33 |
| Januvia | Sitagliptin Phosphate | 160 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 157 | 130 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 42 |
| Sertraline Hcl | Sertraline Hcl | 151 | 42 |
| Memantine Hcl | Memantine Hcl | 148 | 30 |
| Glipizide Er | Glipizide | 147 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 140 | 32 |
| Meloxicam | Meloxicam | 140 | 36 |
| Atenolol | Atenolol | 129 | 35 |
| Simvastatin | Simvastatin | 129 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 38 |
| Farxiga | Dapagliflozin Propanediol | 121 | 21 |
| Ezetimibe | Ezetimibe | 119 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 115 | 29 |
| Bupropion Xl | Bupropion Hcl | 111 | 28 |
| Clonidine Hcl | Clonidine Hcl | 109 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 109 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 104 | 23 |
| Xarelto | Rivaroxaban | 99 | 20 |
| Prednisone | Prednisone | 98 | 52 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 91 | 29 |
| Mirtazapine | Mirtazapine | 89 | 26 |
| Pregabalin | Pregabalin | 87 | 14 |
| Mounjaro | Tirzepatide | 84 | 18 |
| Celecoxib | Celecoxib | 82 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 16 |
| Valsartan | Valsartan | 76 | 20 |
| Ondansetron Odt | Ondansetron | 74 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 70 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 16 |
| Finasteride | Finasteride | 69 | 16 |
| Rybelsus | Semaglutide | 69 | 12 |
| Alendronate Sodium | Alendronate Sodium | 68 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 45 |
| Nifedipine Er | Nifedipine | 63 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 62 | 17 |
| Lorazepam | Lorazepam | 61 | suppressed |
| Spironolactone | Spironolactone | 58 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 15 |
| Myrbetriq | Mirabegron | 56 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 56 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 39 |
| Donepezil Hcl | Donepezil Hcl | 55 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 55 | 16 |
| Glimepiride | Glimepiride | 53 | 17 |
| Mupirocin | Mupirocin | 53 | 27 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 13 |
| Buspirone Hcl | Buspirone Hcl | 44 | 13 |
| Baclofen | Baclofen | 43 | suppressed |
| Entresto | Sacubitril/Valsartan | 43 | 12 |
| Temazepam | Temazepam | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 17 |
| Lactulose | Lactulose | 38 | 14 |
| Linzess | Linaclotide | 38 | 12 |
| Torsemide | Torsemide | 37 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Colchicine | Colchicine | 34 | 15 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Nystatin | Nystatin | 31 | 11 |
| Levemir Flexpen | Insulin Detemir | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 20 |
| Fluconazole | Fluconazole | 28 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 16 |
| Bumetanide | Bumetanide | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 11 |
| Livalo | Pitavastatin Calcium | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 21 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 20 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 13 |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Glyburide | Glyburide | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $83.79 · 5 records | Novo Nordisk Inc | GEMTESA, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error